Media stories about Galectin Therapeutics (NASDAQ:GALT) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 77 out of 100, indicating that recent media coverage is likely to have an impact on the stock’s share price in the next few days.

A number of research analysts have weighed in on the stock. FBR & Co reaffirmed a “market perform” rating and issued a $2.00 price target on shares of Galectin Therapeutics in a research note on Monday, April 3rd. HC Wainwright raised shares of Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Thursday, March 30th. Finally, Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, June 13th.

Galectin Therapeutics (GALT) traded down 0.84% during mid-day trading on Friday, hitting $2.37. 31,328 shares of the stock were exchanged. The stock has a 50 day moving average price of $2.45 and a 200 day moving average price of $1.97. Galectin Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.68. The company’s market capitalization is $82.17 million.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Monday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. On average, equities analysts anticipate that Galectin Therapeutics will post ($0.50) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/07/07/galectin-therapeutics-nasdaqgalt-earning-somewhat-favorable-press-coverage-accern-reports.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.